Faropenem is an orally active beta-lactam antibiotic belonging to the penem group.

The new drug application dossier submitted included these proposed indications:[citation needed] The FDA refused to approve faropenem, an antibiotic manufactured by Louisville-based Replidyne.

The FDA said the drug was “nonapprovable”, but did not refer to specific safety concerns about the product.

The company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections.

[citation needed] In India it is available as Farokaa 200/300 ER and marketed by Troikaa Pharmaceuticals Ltd.